Category - News

Developments

BioSyent signs distribution pact for two CV products

BioSyent (TSX-V:RX; OTC:BIOYF) has signed an exclusive distribution agreement with a European partner for two new products in the cardiovascular therapeutic area for the Canadian market. The products have been approved...

May 25, 2016

Markets

Roth resumes coverage of Fibrocell at buy

Roth Capital Partners has resumed coverage of Fibrocell Science (NASDAQ:FCSC) with a “buy” rating and $7 price target. The stock closed at $2.12 on Monday. Fibrocell leverages its expertise with fibroblasts to target...

May 24, 2016

Developments

Vital enrolls first subject in Phase 3 ELAD trial

Vital Therapies (NASDAQ:VTL) has enrolled the first subject in its Phase 3 trial designated, VTL-308, to evaluate the ELAD System in subjects with severe acute alcoholic hepatitis. ELAD is an extracorporeal human...

May 23, 2016

Developments

Roth adjusts DelMar Pharma price target to $12

Roth Capital Partners has adjusted its price target for DelMar Pharmaceuticals (OTCQX:DMPID) to $12 from $3 after the company’s 1-for-4 reverse stock split. The stock closed at $5.41 on Friday. Analyst Joseph Pantginis...

May 23, 2016

Developments

Anavex gets orphan drug status in Rett syndrome

The FDA has granted orphan drug designation to Anavex Life Sciences’ (NASDAQ:AVXL) ANAVEX 2-73 for the treatment of Rett syndrome. In a statement, Christopher Missling, president and CEO, said orphan drug designation...

May 20, 2016

Developments

FDA grants Profound Medical IDE approval for TULSA-PRO

Profound Medical (TSX-V:PRN) has received investigational device exemption (IDE) approval from the FDA for a multicenter pivotal clinical trial to evaluate the efficacy of the TULSA-PRO System in patients with localized...

May 19, 2016

Developments

BioLight expands portfolio with eye drops for DES

BioLight Life Sciences (TASE:BOLT) has obtained worldwide rights, excluding Israel and Italy, for the manufacturing, distribution, sales and marketing of a groundbreaking new eye drop product for the treatment of dry...

May 19, 2016

Markets

Roth ups Celator Pharma price target to $26

Roth Capital Partners has raised its price target for Celator Pharmaceuticals (NASDAQ:CPXX) to $26 from $22, after the company’s Vyxeos drug candidate received breakthrough therapy designation from the FDA. The stock...

May 19, 2016

Developments

Oramed posts positive oral insulin Phase 2b results

Oramed Pharmaceuticals (NASDAQ:ORMP) has reported positive top-line results from its Phase 2b study, designed to evaluate the safety and efficacy of its oral insulin capsule, ORMD-0801, in patients with Type 2 diabetes...

May 18, 2016

Markets

Leerink downgrades Epirus Biopharma to market perform

Leerink Partners has downgraded Epirus Biopharmaceuticals (NASDAQ:PRS) to “market perform” from “outperform” and slashed its price target to 75 cents from $10. The stock closed at 78 cents on Friday. Analyst Jason...

May 16, 2016

Category - News

Subscribe